Key result
Computational analysis identifies 179 potential drug interactions between tyrosine kinase inhibitors and cardiovascular drugs.
Why the study?
Targeted cancer therapies with tyrosine kinase inhibitors carry recognized short- and long-term adverse effects, particularly cardiovascular toxicities, as lung cancer treatment has progressed.
Computational modeling and interaction checkers identified significant potential pharmacokinetic and pharmacodynamic drug-drug interactions between TKIs and cardiovascular drugs, highlighting the need for careful co-administration in patients with lung cancer and cardiovascular comorbidities.
May warrant caution with TKI-cardiovascular drug co-administration; leaves open need for prospective clinical validation.
<ns3:p>Background As lung cancer treatment has progressed, there has been an increase in awareness of the short- and long-term adverse effects of targeted cancer therapies of tyrosine kinase inhibitors, particularly cardiovascular toxicities. Methods The current study assessed the potential drug-drug interactions using interaction checkers (IBM Micromedex and Drugs.com). Molecular docking was employed to further investigate the involvement of human ether-à-go-go-related gene (hERG) and pregnane X receptor (PXR) proteins to elucidate their potential interactions and their underlying mechanisms. Results A total of 74 pharmacokinetic and 105 pharmacodynamic interactions were detected between tyrosine kinase inhibitors and cardiovascular drugs, along with a report on the severity and level of documentation. A considerable fraction of molecular modelling outcomes concurred with information from drug-drug interaction checkers. The binding energies of tyrosine kinase inhibitors with hERG and PXR were high, indicating significant interactions. The cardiovascular drug class encompasses calcium channel blockers, antiarrhythmic medicines, and statins, which were observed to exhibit synergistic interactions. The identification of these potential drug-drug interactions involving CYP3A4, P-gp, and hERG proteins can be utilized in therapy optimization in clinical settings. Conclusion This study will aid clinicians in designing safe dosage regimens for patients with lung cancer. In cases where patients have multiple comorbidities, it is essential to study the clinical aspects to design efficient chemotherapy and manage adverse effects and toxicities.</ns3:p>
No takes yet. Share an insight, caveat, or question.
Patil et al. (2026) studied Non-Small Cell Lung Cancer with Cardiovascular comorbidities. Tyrosine Kinase Inhibitors and Cardiovascular drugs was evaluated on Potential pharmacokinetic and pharmacodynamic drug-drug interactions. Computational analysis identified 74 pharmacokinetic and 105 pharmacodynamic potential drug-drug interactions between tyrosine kinase inhibitors and cardiovascular drugs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: